Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 12, Issue 1


Volume 10 (2015)

Cell based therapeutic approach in vascular surgery: application and review

Aldo Rocca
  • Corresponding author
  • Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. Via Sergio Pansini, 80131 Naples, Italy
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Domenico Tafuri
  • Department of Sport Sciences and Wellness, University of Naples “Parthenope”, Naples, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Marianna Paccone
  • Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Antonio Giuliani / Anna Ginevra Immacolata Zamboli / Giuseppe Surfaro / Andrea Paccone
  • Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rita Compagna
  • Department of Translational Medical Sciences, University of Naples “Federico II”, Naples, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maurizo Amato
  • Department of Translational Medical Sciences, University of Naples “Federico II”, Naples, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Raffaele Serra / Bruno Amato
  • Department of Translational Medical Sciences, University of Naples “Federico II”, Naples, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-10-21 | DOI: https://doi.org/10.1515/med-2017-0045


Multipotent stem cells - such as mesenchymal stem/stromal cells and stem cells derived from different sources like vascular wall are intensely studied to try to rapidly translate their discovered features from bench to bedside. Vascular wall resident stem cells recruitment, differentiation, survival, proliferation, growth factor production, and signaling pathways transduced were analyzed. We studied biological properties of vascular resident stem cells and explored the relationship from several factors as Matrix Metalloproteinases (MMPs) and regulations of biological, translational and clinical features of these cells. In this review we described a translational and clinical approach to Adult Vascular Wall Resident Multipotent Vascular Stem Cells (VW-SCs) and reported their involvement in alternative clinical approach as cells based therapy in vascular disease like arterial aneurysms or peripheral arterial obstructive disease.

Keywords: Multipotent Stem Cells; Vascular Surgery; Cell-based Therapy; Vascular Progenitors; Arterial aneurysms; Peripheral arterial obstructive disease

1 Introduction

Current and potential therapeutic applications for stem cells are various and complexes. A lot of research fields dealing with stem cells including discovered new sources of highly multipotent stem cells and methods of perpetuating them; creation of induced pluripotent stem cell clones to study genetic disorders or explore pharmacogenomics; utilization in regenerative medicine. Regarding vascular diseased and their treatment by stem cells we provide a brief review of main clinical use of vascular wall resident progenitor cells (VW-PCs). Endothelial cells (ECs), smooth muscle cells (SMCs), and adventitial stromal fibroblasts all derived from mesodermic sheet constitute vascular wall. It is recently demonstrated Recent studies have indicated that resident progenitor cell with angiogenetic properties are located inside arterial wall [1, 2]. These cells arose during embryonic and fetal age, in adult subject remain located in specific niches to guarantee the renewal and repair of vascular tissue and trigger the processes of postnatal angiogenesis [3]. Angiogenesis, characterized by the growth of new blood vessels or capillaries from preexisting vessels, plays a pivotal role in the postnatal tissue remodeling both in physiological and in pathological conditions [4]. Matrix metalloproteinases (MMPs) are enzymes involved in the degradation of the extracellular matrix (ECM) substrates play a regulatory role and participate in key stages of postnatal angiogenesis [5]. Vascularization of several tissues like limbs, retina, and myocardium damaged by ischemia can be restored using hematopoietic progenitors as well as bone marrow-derived endothelial cells. [6, 7, 8, 9, 10]. It is also demonstrated that quiescent multipotent stem cells (SCs) reside in the vascular wall; in sites of vascular pathology like arterial aneurysms they can be activated and differentiate into SMCs [11, 12, 13]. Different MMPs expression can regulate wall resident SC biological properties releasing growth factors and activating signaling pathways. [14, 15, 16]. The purpose of this review is to examine the role of vascular wall resident stem cells in therapy like restoring vasculature after ischemic events and mainly provide a huge analysis of biomolecular mechanisms that regulate the involvement of vasculature progenitors and the activity of MMPs in natural history of arterial aneurysms.

2 Biology of vascular stem cells

Several studies were made well assess the physiology of stem cells and a lot of factors which maintain stemness [17, 18, 19, 20, 21, 22, 23]. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are predominantly descendants of mesodermal cells; nevertheless, some Authors described an ectoderm origin for VSMCs [24, 25]. Many factors regulate the differentiation of mesoderm in vascular cells and this process is really complex and finely regulated. Blood vessels arise from endothelial precursors through a process known as developmental vasculogenesis [26, 27]. Angiogenesis, also called collateral growth, is the transformation of preexistent collateral arterioles into functional collateral arteries could be induced by human bone marrow-derived stromal cells through paracrine mechanisms [28, 29]. The expression of a lot of growth factors and cytokines, such as VEGF and stromal derived factor-1a (SDF-1a) is regulated by hypoxia-inducible factor-1a (HIF-1a) whose activation should be ascribe to the drop in O2 tension observed in hypoxic tissues or tumors [30]. The release of VEGF and SDF-1a into peripheral circulation lead to recruitment of hematopoietic cells like CFU-ECs and CACs in affected tissues. Afterwards these factors activating angiogenesis process utilizing intracellular Ca2+ signals toolkit. [31, 32, 33, 34, 35, 36, 37, 38, 39]. Immature VSMCs are still involved in blood vessel morphogenesis. They are able to proliferate, migrate and produce extracellular matrix (ECM) components of the blood vessel wall. The process of VSMV differentiation is triggered by a lot of vascular growth stimuli, such as ischemic injury. Ischemic damage involves matrix proteases, known as matrix metalloproteinases (MMPs). MMPs, thus, are involved in several vascular [40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54] and nonvascular diseases [55].

3 Adult vascular wall resident stem cells and angiogenesis

It is clearly know that several progenitor cells and stem cells are hidden in arterial and venous vessels. Various type of cells are involved like endothelial progenitor cells (EPCs), smooth muscle cell (SMC) progenitors, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and the mesangial cells, which express either endothelial either myogenic markers [56, 57, 58, 59]. Cells expressing CD 34, vascular endothelial growth factor 2 receptor (VEGFR2) and tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE2). Were identified between media and adventitia of human vessels. These cells have the power to switch into ECs, either in physiological pathways either in pathological pathways [14, 59, 60, 61, 62]. In human arteries and veins we can find also CD44(+) CD34(−) CD45(−) multipotent MSC-like stem cells, these cells can differentiate into pericytes/SMC. Researchers have demonstrated that these cells are capable to cover the endothelium of new vessels in vivo and in vitro conditions [63]. CD 34+ and sca1+ cells are part of Sonic Hegehog pathway, and they are placed in the inner part of adventitia of arteries in animal models. They seem to build a vasculogenic area [64]. This area plays a central role in the resource of progenitor cells related to the EPCs which circulate and derive from bone marrow. Moreover they are also a reserve for local immune response in the inflammation pathways [65]. In these zones we can find also VW-PCs during their growth from the embryonic phase to adult one. VW-PCs can become SMC and pericytes and have the power to build new capillary sprouts and go towards angiogenic lineage [66]. Vasculogenesis is known as the formation of new vessels from angioblasts, this is the most important pathway involved in blood island vessels formation, dorsal aorta, endocardium, and vitelline vessels in the embryo. On the other hand angiogenesis is known as the formation of new vessels from other vessels in response to pathological or physiological conditions [67]. In this pathway are involved endothelial cell migration, proliferation, and tube formation [68, 69, 70]. An important reservoir of non differentiated cells is made by VW-PCs ready to answer to cellular demands modifying their phenotypical characteristics [71]. Neovascularization is linked to endothelial cells, their migration and proliferation ability, and coverage of vessels performed by pericytes. Pericytes allow stabilization and survival of new sprouting vessels; Researchers found either in vivo either in vitro that VW-PCs can differentiate into vascular SMCs and pericytes [72]. During angiogenesis an important reservoir of pericytes and SMCs can be supplied by MSCs in physiological and pathological conditions. After a vascular injury these cells occur to repair the damaged vascular cells [73, 74, 75, 76].

4 Regulatory role of MMPs on vascular wall resident stem cells

MMPs, are a group of zinc dependent proteinases consisting of 28 family members that are able to degrade ECM compounds and other proteins [77] taking a pivotal role in vascular remodeling [78].

Serra et al. have demonstrated MMPs involvement in a lot of vascular diseases [4, 79, 80, 81, 82, 83, 84]. Angiogenesis process start with ECM degradation by proteinases leading to release of several factors such as growth factors and their receptors, adhesions molecules, chemokines and apoptosis mediators as well as cell migration [30, 85, 86,]. VW-PCs acquired the ability to differentiate into a smooth muscle cells (SMCs) and pericytes that synthesize some proteins of basement membrane like proteoglycans and various types of collagens [87, 88, 89]. Vascular basement membrane (VBM) is a specialized extracellular matrix that surrounds the blood vessels of the body and interacts with paralytic MSCs regulated through an interplay between proteases and protease inhibitors influencing vessel homeostasis and vascular diseases like vessel aneurysms [90, 91, 92, 93, 94, 95, 96]. In pericyte–EC interface there are a lot of proteins like fibronectin and a compounds of different type of junctions like tight, gap as well as N-cadherin and b-catenin-based adherens junctions [97]. Fibronectin is degraded by proteolytic enzymes such as MMPs rising biologically active fragments like a 45 kDa fibronectin fragment, involved in vascular remodeling and maturation [98]. MMPs represent the main proteolitic enzyme involved leading to release of angiogenic factors [99, 100, 101]. SMCs can express MMP-7 and MMP-3 and express and secrete MMP-2 and MMP-9 under the control of NF-kB. Moreover, MMPs can be released by leucocyte while SMCs are the main source of tissue protease inhibitors [102, 103]. They also constitutively express and secrete several serine proteases [104, 105]; thus, in the vascular wall, SMCs are the main source of TIMPs [106]. As recently reported the expression of Homeobox C11 (HOXC11) results in drastic vessel wall remodeling [107, 108]. MMP-8 and MMP-9 initiate a cascade of events including release and activation of mobilizing factors and cytokines, ECM degradation and remodeling [109, 110, 111, 112]. MMPs are also related to mitogenesis and migration of SMCs [113]. In in vivo studies, MMP-3 knockout mice reduced neo-intima formation after carotid ligation and also attenuated SMCs migration into wound [114]. SMCs are important both to promote arterial remodeling and to modify vessel diameter and/or wall thickness to ensure adequate tissue perfusion [115]. In presence of VEGF, arterial wall resident cells became round-shaped, resembling ECs, and part of the cells acquired CD-31, VE-cadherin, and von Willebrand factor expression, whereas when they are cultured with TGFβ-1 or platelet derived growth factor-BB (PDGF-BB) adopted a rather elongated phenotype, similar to that of SMCs, and part of the cells acquired anti-α-smooth muscle actin (ASMA) and calponin [116]. VEGF also induces the expression of Notch1 through PI3K/AKT pathway in cultured ECs [117]. The roles of Notch include the differentiation in both EPCs and SMC via activation of transcriptional CBF-1/RBP-Jκ-dependent and independent pathways and transduction of downstream Notch target gene expression [118, 119]. These angiogenic factors can induce differentiation from progenitor in media to EPCs and SMCs [14]. Recently it has been shown that pericytes are able to detach from the vascular wall and contribute to fibrosis by becoming scar-forming myofibroblasts in many organs including the kidney. At the same time, the loss of pericytes within the perivascular compartment results in vulnerable capillaries which are prone to instability, pathological angiogenesis, and, ultimately, rarefaction such as aneurysmal disease [120, 121]. Based on these evidences, we could affirm that MMPs may play a central role to regulate the activity of the VWPCs by increasing the bio-disponibility of main proangiogenic factors. Another role of MMPs is to promote the differentiation and migration of fibroblast and resident vasculogenic progenitors critically involved in vascular repair by remodeling of ECM [122]. MMPs contribute to VW-PCs during the progression of arterial aneurysms and participate in all crucial stages of this degenerative disease.

5 Vascularwall resident cells and aneurysms

Vascular accidents are very frequent in the western countries, and aneurisms are one of the most important one. Several conditions are linked to aneurism incidence such as alterations of glucose and lipid metabolism, hypertension, trauma, anastomotic disruption, infections, and connective or inflammatory diseases. As already described, arterial aneurysms are divided into central aneurysms, like abdominal aortic aneurysms, and peripheral aneurysms, like aneurysms of the popliteal, femoral, and carotid arteries [123,124]. Two are the pathogenic keys in the aneurismal formation, medial degenerations and vessel dilatation: low activities of MMPs [125] and Death SMCs causes poor synthesis of elastine [126]. Artery wall is progressively destroyed by ROS damage and chronic inflammation. As already described, in arterial wall are preserved resident stem cells [82, 127, 128, 129]. So in the vasculogenic area are hidden VWPCs which are involved in the formation of perycites/SMCs. During endothelial injuries VW-PCs and SMCs evolve to proliferate, migrate and differentiate. This mechanism allow damage repair [130, 131]. SMCs derived from differentiation of VW-PCs occurs at the injury site and migrate into the intima [132]. Adventitia release factors that activate and regulate VW-PCs wall function. Resident stem cells are involved also in structural modifications of artherosclerotic disease acquiring specific structural and morphological features [133, 134]. So is clear that in pathological conditions vasculogenic area plays a central role in the wall injury [135]. Literature underline how other enzyme and cytokynes can influence the mobilization of these cell from their residence zone. These factors are tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), and stromal cell derived factor 1-alpha (SDF1-α). Reserchers demonstrated that adventitia inflammation allows mobilization of progenitor cells via vasa vasorum [136]. Arterial aneurisms and VW-PCs are probably linked. We have find a description of stem cells role in inflammatory pathway of abdominal arterial aneurism (AAA) by Ryer et al. after analysis of several patients underwent to surgery for infrarenal aneurismal repair. Researchers found a great amount of ckit+ and CD34+ cells. On the other hand they find macrophage marker CD68 expression. But they didn’t find SM22 as SMCs marker or FSP1 as fibroblast marker. We know also that CD68+ cells are present at the time with the cellular marker of proliferation Ki67 [131]. So resident stem cells appears to have an important role in pathogenesis of AAA as described and confirmed also by other authors [137,138]. It has been shown that hemodynamic influence stem cells differentiation. Shear stress is linked to endothelial differentiation pathway, on the other side cyclic forces improves smooth muscle cells proliferation. These abnormal differentiation stimuli allow wall disease and lead to aneurism formation [135]. Certain authors like Witte et al. affirm that vacuoles in VW-PCs are the probe of their ability to form capillary lumen. These cells can go or on the side of differentiation or on the side of nescrosis, if RBC goes into the vacuole they go to the necrosis pathway [138]. Afetr tissue injury VW-PCs express CD-34, STRO-1, c-Kit, so they acquire the ability to differentiate into SMCs and fibroblasts, this admit the hypothesis that they have a key role in a repair and remodeling process [120]. To differentiate into ECs and MSCs are required stimuli by angiogenetic citokyne like VRGF, which is stimulate by C-kit cells [139]. The degradation of arterial wall ECM components increased by MMPs activation is the basic moment in aneurismal formation. [140, 141]. MMPs, expecially MMP-2 and MMP-9, are released in the aortic wall by SMCs and macrophages. [142, 143]. To occur vascular aneurism is required that medial fibers are impaired, a diminution of SMC and invasion of inflammatory cells in the vascular wall. ECM are strictly linked to its synthesis by SMCs and protease activation. Chronic inflammation due to an aneurismal history cause a diminution of SMCs with vascular impairment and reduction of production of elastine and basement membrane. All of these findings cause the loss of organization of extracellular matrix [70, 144, 145, 146]. In neo-intimal lesions and adventitia of atherosclerotic plaques of human corps after autopsies several authors showed the presence of CD34+Sca1+CD133– cells. These cells might be at the origin of endothelial and vascular smooth muscle cells that are at the base o f atherosclerosis [147, 148, 149, 150]. Also pericytes are involved in vascular inflammatory response as described by Tigges et al. in restenosis of femoral arteries injuries in mices [82, 151] They contribute to intima hyperplasia due to their mesenchymal stem cell like behavior [152, 153]. VSMs are most representative cells in the media and can perform pro-inflammatory response to several stimuli. Macrophage and t-cells are affected by media cytochines and chemochines, but on contrary VSMCs and EMC can perform also anti-inflammatory pathways. The opposition between the two forces impacts the medial pathology. The medial immune privilege defends the media from injury and inflammation, it provides the typical arteriosclerotic lesions, as the first step of aneurysmal disease. On the contrary when the medial immune privilege is lost. We observe a severe leukocytic infiltrates, loss of VSMCs with alterations of the extracellular matrix architecture. With augmentation of incidence of aneurismal disease and vasculitides [154, 155]. Also CD4+ T cells, CD8+ T cells, and B cells are involved in the immune response in vascular tissues, they are stimulated by factors from apoptotic cells, necrotic cells microvasculature injury, and stroma [156, 157]. Insufficient inflammatory cytokines during chronic inflammatory sites, however, are able to induce MSCs to secrete chemokines and tropic factors without immune inhibitory factors. Son chronic inflammation may lead MSCs to protract the disease recovery or even worsen the disease course such us in aneurysmal disease [158, 159]. From the bone marrow also osteoblast and osteoclast precursor (also known as osteoprogenitors) could be able to create a process of calcification. According the circulating cell theory from the bone marrow the cell population of osteoprogenitors (OP) could seed the arteries and could be responsible of the damage or, instead, could repair it [160, 161, 162]. It is also possible the mechanism of homing: in response to a damage, an injury, an inflammatory phenomena, a stress signal, or in response to an abnormal cytokine signaling or also only to repair the damage, the circulating OP could be recruited in the arteries; they could cross the endothelium, they could invade the target tissue [163, 164]. The homing depends by the endothelial phenotype: every endothelial phenotype has different functions. So, the homing of bone marrow derived stem cells is modulated by endothelial phenotype. In the coronary artery endothelium, for example, is possible a fastest integration of the bone marrow stromal cells. It is essential the interation of vascular cell adhesion molecule molecule-1, very late antigen-4, β1integrins, MMPs secretion, and cytokines [165, 166]. Another important molecule is BMP-2, expressed by pericytic myofibroblasts; it is a powerful bone morphogenic factor. According some studies, in the pathogenesis of atherosclerosis could be involved the MSC because in culture they acquires an osteoblastic phenotype as the WNT pathway is activated [167, 168]. It was noticed in rats with hyperlipidemia and treated with angioplasty that paracrine BMP-2 (one of the most important mediators in the differentiation of MSC along the osteoblastic lineage) mediates the remodeling and it triggers calcification of the vessel walls [169, 170]. It is also known that pericytes represent a reservoir of progenitors cells (including osteoblasts) [171, 172], and they can differentiate themselves into various cell lines, also the chondro and osteogenic ones [173, 174]. This is an interesting example of how the interation among different cells of vessel wall can bring to the calcification. The suppression of MMP by the VW-PCs could be a fundamental element to reduce the aneurismal degeneration. It is also possible that tissue damage could be induced by differentiation of VW-PC into inflammatory cells. The presence of macrophages that are involved into the replenishment of the aneurysm wall probably is due to the VW-PC. It is clear, so, that the vW-PC could be responsible both of the inflammatory state and aneurismal degeneration both of the vascular repair. Different factors are involved, for example cytokines, growth factors, and the activation of specific pathway [175].

6 MSCs application in cardiovascular regenerative therapy

The interest of many studies is concentrated on VW-PC, on circulating EPCs and on umbilical cord blood cells because they can be used for the treatment of many different diseases. The vascular disorders, for example, could be treated using the EPC; the EPC can migrate through the blood, can differentiate into new endothelial cells so that the process of neoangiogenesis can be induced, the endothelium (also of damaged tissues that are distant) can be repaired [176, 177]. The vascular repair, in fact, can be obtained if the EPC can be mobilized from the bone marrow into the peripheral circulation or if the EPC situated into the vascular wall can be activated; EPC form the endothelial cells that are incorporated into the endothelial layer of the injured area to repair the lesion size [186]. It is clearly demonstrated and previously described that VEGF, as well as many other growth factors, utilize are able to activate neoangiogenesis utilizing Ca2+ signaling toolkit which regulates EPCs biological properties like differentiation, proliferative rate, migration and vessel tube formation. Intracellular Ca2+ signals toolkit could be manipulate to repair damaged tissue using genetically transformed cells or represent the target site of cell based therapy through the impairment of EPC-dependent vasculogenesis and adverse tumour neovascularization [178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192]. Also MSC are useful to reduce a lesion because they could be able to stop the process of fibrosis, apoptosis, and could be responsible to induce mitosis in intrinsic cellular progenitors [193]. The reduction of functions of B and T lymphocytes and NK is the cause of these immunomodulating effects [194, 195]. The MSC has not a great immunogenic effect, because of the low levels of HLA–I and the null expression of HLA-II [196, 197]. The MSC could have a reparative effect if administered after an acute event, as demonstrated in porcine with myocardial effect [198, 199, 200, 201]; the MSC could also have the ability of differentiate into cells with biologic characteristics of cardiac myocytes and endothelial cells, with the result of an improvement of cardiac function, if compared with untreated controls [202, 203]. Also the postnatal skeletal muscle is able to repair and regenerate itself but in some particular pathological conditions, for example, muscular dystrophy or compartment syndrome, the myogenic progenitors are not be able to do it [204, 205, 206, 207]. To prove the structural and functional regeneration of human myofibers, pericytes purified from human myofibers, from fat, pancreas and placenta, were transplanted into mouse with dystrophy and in cardiotoxin treatment; it was noticed that there was a more efficient regeneration than do myoblasts or endothelial cells. There was also a surprising improvement also with pericytes isolated from patients with Duchenne muscular dystrophy [208, 209, 210]. A specific cellular type can be used only in a specific treatment. For example, to obtain the bone regeneration or dental repair or adipose reconstruction can be used the pericytes (studies have demonstrated that osteogenic, odontoblastic and adipogenic progenitors originate from perivascular niches) [211]. MSCs and pericytes derived from cord blood may have a great therapeutic efficacy also in the complete restoration of kidney function, if compared with MSC derived form regular bone marrow; they could seem to secret angiogenic and antiapoptotic factors that could be responsible of renoprotective effects [212, 213]. Furthemore, the umbilical cord is another source of stem cells [214, 215, 216]. The pericytes could be useful for many therapies. They can migrate toward the damaged cells, and can produce the vascular endothelial growth factor and keratinocyte growth factor, with antiapoptotic and angiogenic properties, so it is possible to obtain the vascular repair [217, 218, 219, 220, 221]. The same MSC are present not only in bone marrow but also around adult vessels; these MSC-like cells seem to be responsible of vasculogenesis, arteriogenesis, angiogenesis. With no doubt, using the MSCs and the MSC-like cells there are no ethical problems, but the only problem is that we don’t know their specific mechanisms of action. Different elements have to be considered. Release of vasculogenic-angiogenic factors and/or arteriogenic-stimulating factors, immunomodulation into a different microenviroment, differentiation into vascular tissue, but also cell source, administration route, cell dosage, timing of cell delivery, are important factors to take in consideration. Many different results have been observed and probably are due to other many variables, for example drugs, diseases, inflammatory status, and comorbidities. Studies in vivo demonstrated that MMP activity was inhibited by MSCs and TIMP-1 was influenced by MSCs, instead MMP-2 activity was suppressed ex-vivo. Studies in vitro, instead, showed how MM gene expression in macrophages was suppressed by MSCs. There was, also, a negative correlation between elastin content and MMPs. It was described a reduced expression of inflammatory cytokines, as IL-6, MCP-1, TNF-α, probably implicated in the up-regulation of MMP in the aortic wall. It is probably true that paracrine mechanisms induced by MSCs could be stop the immunopathologic reactions in the aneurismal vascular wall. As regards MSCs coming from bone marrow, they could seem inhibited in vitro the activity of dendritic cells, T cells, NK cells. MMP2 and MMP 9, elastases and chemokines are responsible of induction of mobilization and homing of MSC; MSC is known also to have particular tropism for inflammation. Important elements of AA are represented by chronic inflammation of the aortic wall induced by chemokines and aortic ECM degradation by MMP-2 and MMP-9, so MSCs that migrate toward MMPs and Chemokines can be useful for therapy of aortic aneurysm [222, 223, 224, 225].

7 Discussion

SCs research is both scientifically promising and ethically challenging. In vascular diseases like arterial aneurysm the complexity of pathogenesis involving inflammation, MMPs activation, ECM remodeling, and VSMC dysfunction and apoptosis lead to the weakening of the vessel wall and arterial expansion under the influence of mechanical stimuli [226, 227]. Several complications like rupture, dissection, and distal embolization are frequently observed [228]. The degenerative remodeling seen in arterial aneurysms can result from a combination of excessive destruction and insufficient repair in which SCs play an important role creating a useful microenvironment for vascular regeneration [229]. VW-PCs have been also isolated from the thoracic and abdominal aortas of humans. A specific zone of vascular wall named vasculogenic zone contains specific subpopulation of EPCs [32]. In arterial aneurysms the chronic inflammation lead to MMPs activation inducing the mobilization of local VW-PCs and tissue-resident EPCs involved in an active repair process involving SCs. VW-PCs promote vascular repair by differentiating into vascular SMCs and fibroblasts in vasa vasorum localized in adventitial layer of vascular wall. MMPs activation can induce the secretion of pro-angiogenic cytokines such as VEGF and stimulate host SCs proliferation and differentiation. Share stress is also involved in arterial aneurysms pathophysiology. Arterial ECs proliferation and migration and medial SMC proliferation promotes adaptive enlargement and luminal tortuosity of vascular wall. A lot of papers report that proteolytic activity of ECM degradation by MMPs play a critical role in vascular formation and remodeling promoting the synthesis of pro-angiogenic growth factors and cytokines. Vascular formation and remodeling include recruitment, migration, proliferation, and apoptosis of vascular cells consisting of stem/ progenitor cells, ECs, VSMCs, and other cells located in vascular wall. MMP-2, MMP-9, MT1-MMP, MMP-3, MMP-1, and MMP-7 have been recognized in vascular tissue and play pathogenic roles in vascular remodeling via regulating VSMC behaviors [230]. Early outgrowth EPCs induce only transient angiogenesis by secretory activity. Late out-growth cells probably produce the effect by direct engraftment [231, 232]. VW-PCs exert their functional role in different phases of the natural history of aneurysms. In the early stages, the activity of MMPs lead to growth factors release. Stem cells are quiescent and reside in stem cell niches of the vessel wall but several stimuli can lead their activation. If damage is moderate, the laminar flow will stimulate stem cells to differentiate into ECs to maintain the vessel integrity. When severe damage or atherosclerotic lesion occurs, locally the disturbed flow is induced, resulting in stem cell differentiation towards SMCs, which accumulates within the intima [233, 234]. The existence of VW-PCs provides an exciting prospect to directly manipulate local responses within the vasculature, as it has already happened, in a similar way, in cell therapy for critical limb ischemia [235].


  • [1]

    Pacilli A., and Pasquinelli G., Vascular wall resident progenitor cells. A review, Experimental Cell Research 2009, 315, (6): 901-914 PubMedCrossrefGoogle Scholar

  • [2]

    Käßmeyer S., Plendl J., Custodis P., and Bahramsoltani M., New insights in vascular development: vasculogenesis and endothelial progenitor cells, Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia. 2009, 38, 1, 1-11 Google Scholar

  • [3]

    Ergün S., Tilki D., Hohn H.P., Gehling U., and Kilic N., Potential implications of vascular wall resident endothelial progenitor cells, Thrombosis and Haemostasis, 2007, 98, 5, 930-939 PubMedGoogle Scholar

  • [4]

    Serra R., G. Buffone G., Costanzo G., Montemurro R., Scarcello E., Stillitano DM., et al., Altered metalloproteinase-9 expression as least common denominator between varicocele, inguinal hernia, and chronic venous disorders, Annals of Vascular Surgery, 2014, 28, 3, 705-709 PubMedCrossrefGoogle Scholar

  • [5]

    Barnett J.M., McCollum G.W., Fowler J.A., Duan J.J., Kay J.D., Liu R.Q., Bingaman D.P., Penn J.S., Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR, Investigative Ophthalmology and Visual Science, 2007, 48, 2, 907-915 CrossrefGoogle Scholar

  • [6]

    Goldenberg-Cohen N., Avraham-Lubin B.C.R., Sadikov T., and Askenasy N., Effect of co administration of neuronal growth factors on neuroglial differentiation of bone marrow derived stem cells in the ischemic retina, Investigative Ophthalmology & Visual Science, 2013, 55, 1, 502-512 Google Scholar

  • [7]

    Schutt R.C., Trachtenberg B.H., Cooke J.P., Traverse J.H., Henry T.D., Pepine C.J., et al., Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans, Circulation, 2002, 106, 15, 1913-1918 CrossrefPubMedGoogle Scholar

  • [8]

    Amato B., Compagna R., della Corte G.A., Martino G., Bianco T., Coretti G. et al., Peripheral blood mono-nuclear cells implantation in patients with peripheral arterial disease: a pilot study for clinical and biochemical outcome of neoangiogenesis, BMC Surgery, 2012, 12, supplement 1, article S1 PubMedGoogle Scholar

  • [9]

    Franz R.W., Parks A., Shah K.J., Hankins T., Hartman J.F., and Wright M.L., Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease, Journal of Vascular Surgery, 2009, 50, 6, 1378-1390 PubMedCrossrefGoogle Scholar

  • [10]

    Randall W. Franz., Kaushal J. Shah., Jason D. Johnson., Richard H. Pin, Alan M. Parks, Thomas Hankins, et al., Short- to midterm results using autologous bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease, Vascular and Endovascular Surgery, 2011, 45, 5, 398-406 CrossrefGoogle Scholar

  • [11]

    Newby A.C., Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates, Cardiovascular Research, 2006, 69, 3, 614-624 PubMedCrossrefGoogle Scholar

  • [12]

    Williams A.R., and Hare J.M., Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease, Circulation Research, 2011, 109, 8, 923-940 Google Scholar

  • [13]

    Goligorsky M.S., and Salven P., Concise review: endothelial stem and progenitor cells and their habitats, Stem Cells Translational Medicine, 2013, 2, 7, 499-504 CrossrefPubMedGoogle Scholar

  • [14]

    Torsney E. and Xu Q., Resident vascular progenitor cells, Journal of Molecular and Cellular Cardiology, 2011 50, 2, 304-311 Google Scholar

  • [15]

    Yeager M.E., Frid M.G., and Stenmark K.R., Progenitor cells in pulmonary vascular remodeling, Pulmonary Circulation, 2011, 1, 1, 3-16 CrossrefPubMedGoogle Scholar

  • [16]

    Zhang M., Malik A.B., and Rehman J., Endothelial progenitor cells and vascular repair, Current Opinion in Hematology, 2014 21, 3, 224-228 PubMedCrossrefGoogle Scholar

  • [17]

    Kiskinis E. and Eggan K., Progress toward the clinical application of patient-specific pluripotent stem cells, The Journal of Clinical Investigation, 2010, 120, 1, 51-59 PubMedCrossrefGoogle Scholar

  • [18]

    Rustad K.C., Wong V.W., Sorkin M., Glotzbach J.P., Major M.R., Rajadas J., et al., Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold, Biomaterials, 2012, 33, (1), 80-90. . Epub 2011 Oct 2 CrossrefPubMedGoogle Scholar

  • [19]

    Vogel G., Stemness genes still elusive, Science, 2003, 302, 5644, article 371 Google Scholar

  • [20]

    Evsikov A.V. and Solter D., Comment on Stemness: transcriptional profiling of embryonic and adult stem cells and a stem cell molecular signature, Science, 2003, 302, 5644, 393-393 Google Scholar

  • [21]

    Gerrits A., Dykstra B., Otten M., Bystrykh L., and De Haan G., Combining transcriptional profiling and genetic linkage analysis to uncover gene networks operating in hematopoietic stem cells and their progeny, Immunogenetics, 2008, 60, 8, 411-422 CrossrefPubMedGoogle Scholar

  • [22]

    Bhattacharya B., Puri S., and Puri R.K., A review of gene expression profiling of human embryonic stem cell lines and their differentiated progeny, Current Stem Cell Research and Therapy, 2009, 4, 2, 98-106 CrossrefGoogle Scholar

  • [23]

    Zhu D., Wan X., Huang H., Chen X., Liang W., Zhao F. et al., Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells, Oncology Reports, 2014, 31, 2, 727-736 CrossrefPubMedGoogle Scholar

  • [24]

    de Felici M., Farini D., and Dolci S., In or out stemness: comparing growth factor signalling in mouse embryonic stem cells and primordial germ cells, Current Stem Cell Research and Therapy, 2009, 4, 2, 87-97 CrossrefGoogle Scholar

  • [25]

    Topouzis S. and Majesky M.W., Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-β, Developmental Biology, 1996, 178, 2, 430-445 PubMedGoogle Scholar

  • [26]

    Voskuil M., van Royen M.N., Hoefer I., Buschmann I., Schaper W., and Piek J.J., Angiogenesis and arteriogenesis: the long journey from concept to clinical application, Nederlands Tijdschrift voor Geneeskunde, 2001, 145, 14, 670-675 Google Scholar

  • [27]

    van Royen N., Piek J.J., Buschmann I., Hoefer I., Voskuil M., and Schaper W., Stimulation of arteriogenesis; a new concept or the treatment of arterial occlusive disease, Cardiovascular Research, 2001, 49, 3, 543-553 CrossrefPubMedGoogle Scholar

  • [28]

    Eitenmüller I., Volger O., Kluge A., Troidl K., Barancik M., Cai W.J., et al., The range of adaptation by collateral vessels after femoral artery occlusion, Circulation Research, 2006, 99, 6, 656-662 CrossrefPubMedGoogle Scholar

  • [29]

    Heil M. an Schaper W., Influence of mechanical, cellular, and molecular factors on collateral artery growth (Arteriogenesis), Circulation Research, 2004, 95, 5, 449-458 CrossrefPubMedGoogle Scholar

  • [30]

    Carmeliet P., Jain R.K., Molecular mechanisms and clinical applications of angiogenesis, Nature, 2011, May 19, 473, (7347), 298-307.  CrossrefPubMedGoogle Scholar

  • [31]

    Moccia F., Guerra G., Ca2+ Signalling in Endothelial Progenitor Cells: Friend or Foe? J Cell Physiol, 2016, Feb, 231, (2), 314-27,  CrossrefGoogle Scholar

  • [32]

    Moccia F., Zuccolo E., Soda T., Tanzi F., Guerra G., Mapelli L., et al., Proteins in neuronal Ca(2+) signaling and excitability, Front Cell Neurosci. 2015 Apr 24, 9, 153,  CrossrefPubMedGoogle Scholar

  • [33]

    Dragoni S., Guerra G., Pla A.f., Bertoni G., Rappa A., Poletto V., et al., A Functional Transient Receptor Potential Vanilloid 4 (Trpv4) Channel Is Epxressed In Human Endothelial Progenitor Cells, J Cell Physiol, 2015, Jan, 230, (1), 95-104,  CrossrefPubMedGoogle Scholar

  • [34]

    Potenza D.M., Guerra G., Avanzato D., Poletto V., Pareek S., Guido D., Gallanti A., et al., Hydrogen sulphide triggers VEGF-induced intracellular Ca2+ signals in human endothelial cells but not in their immature progenitors, Cell Calcium, 2014 Sep, 56, (3), 225-34,  CrossrefGoogle Scholar

  • [35]

    Moccia F., Dragoni S., Cinelli M., Montagnani S., Amato B., Rosti V., et al., How to utilize Ca2+ signals to rejuvenate the reparative phenotype of senescent endothelial progenitor cells in elderly patients affected by cardiovascular diseases: a useful therapeutic support of surgical approach? BMC Surg, 2013 Oct 8, 13, (Suppl 2), S46,  CrossrefGoogle Scholar

  • [36]

    Sánchez-Hernández Y., Laforenza U., Bonetti E., Fontana J., Dragoni S., Russo M., Store operated Ca2+ entry is expressed in human endothelial progenitor cells, Stem Cells and Development, 2010 Dec, 19, (12), 1967-81,  CrossrefGoogle Scholar

  • [37]

    Ronco V., Potenza D.M., Denti F., Vullo S., Gagliano G., Tognolina M., et al.: A novel Ca2+-mediated cross-talk between endoplasmic reticulum and acidic organelles: implications for NAADP-dependent Ca2+ signaling, Cell Calcium, 2015, 57, (2), 89-100,  CrossrefGoogle Scholar

  • [38]

    Dragoni S., Laforenza U., Bonetti E., Lodola F., Bottino C., Guerra G., et al., Canonical transient receptor potential 3 channel triggers VEGF induced intracellular Ca2+ oscillations in endothelial progenitor cells isolated from umbilical cord blood, Stem Cells Dev, 2013, 22, 2561-2580,  CrossrefPubMedGoogle Scholar

  • [39]

    Dragoni S., Laforenza U., Bonetti E., Lodola F., Bottino C., Berra-Romani R., Carlo Bongio G., et al. Vascular endothelial growth factor stimulates endothelial colony forming cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca2+ concentration, Stem Cells, 2011, 29, 1898-1907,  CrossrefPubMedGoogle Scholar

  • [40]

    Serra R., Buffone G., Costanzo G., Montemurro R., Scarcello E., Stillitano DM. et al., Altered metalloproteinase-9 expression as least common denominator between varicocele, inguinal hernia, and chronic venous disorders, Annals of Vascular Surgery, 2014, 28, 3, 705-709 PubMedCrossrefGoogle Scholar

  • [41]

    Amato B., Coretti G., Compagna R., Amato M., Buffone G., Gigliotti D. et al., Role of matrix metalloproteinases in non-healing venous ulcers, Int Wound J. 2015 Dec, 12, (6), 641-5.  CrossrefPubMedGoogle Scholar

  • [42]

    Serra R., Buffone G., Falcone D., Molinari V., Scaramuzzino M., Gallelli L., de Franciscis S., Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin, Wound Repair Regen, 2013 May-Jun, 21, (3), 395-401.  CrossrefPubMedGoogle Scholar

  • [43]

    Serra R., Grande R., Buffone G., Gallelli L., De Franciscis S. The effects of minocycline on extracellular matrix in patients with chronic venous leg ulcers, Acta Phlebologica, 2013, 14, 3, 99-107 Google Scholar

  • [44]

    Serra R., Grande R., Butrico L., Buffone G., Caliò F.G., Squillace A., et al., Effects of a new nutraceutical substance on clinical andmolecular parameters in patients with chronic venous ulceration, Int Wound J., 2016, 13, (1), 88-96.  CrossrefGoogle Scholar

  • [45]

    Serra R., Gallelli L., Buffone G., Molinari V., Stillitano D.M., Palmieri C., de Franciscis S., Doxycycline speeds up healing of chronic venous ulcers, Int Wound J. 2015 Apr, 12, (2), 179-84.  CrossrefPubMedGoogle Scholar

  • [46]

    Serra R., Gallelli L., Conti A., De Caridi G., Massara M., Spinelli F., Buffone G. et al., The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs, Drug Design, Development andTherapy, 2014, 8, 519-527 Google Scholar

  • [47]

    Serra R., Grande R., Buffone G., Molinari V., Perri P., Perri A., et al., Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines, International Wound Journal, 2016, 13, (1), 53-8.  CrossrefPubMedGoogle Scholar

  • [48]

    Busceti M.T., Grande R., Amato B., Gasbarro V., Buffone G., Amato M. et al., Pulmonary embolism, metalloproteinases and neutrophil gelatinase associated lipocalin, Acta Phlebologica, 2013, 14, 3, 115-121 Google Scholar

  • [49]

    S. de Franciscis, P. Mastroroberto, L. Gallelli, G. Buffone, R. Montemurro, and R. Serra, Increased plasma levels of metalloproteinase-9 and neutrophil gelatinase associated lipocalin in a rare case of multiple artery aneurysm, Annals of Vascular Surgery, 2013, 27, 8, 1185.e5-1185.e7 Google Scholar

  • [50]

    de Franciscis S., Gallelli L., Battaglia L., Molinari V., Montemurro R., Stillitano DM., Buffone G., Serra R., Cilostazol prevents foot ulcers in diabetic patientswith peripheral vascular disease, Int Wound Journal, 2015, 12, (3), 250-3.  CrossrefGoogle Scholar

  • [51]

    Serra R., Grande R., Gallelli L., Rende P., Scarcello E., Buffone G., Caliò F.G., Gasbarro V., Amato B., de Franciscis S., Carotid body paragangliomas and Matrix metalloproteinases, Annals of Vascular Surgery, 2014, 28, (7), 1665-70.  CrossrefPubMedGoogle Scholar

  • [52]

    de Franciscis S., Grande R., Butrico L., Buffone G., Gallelli L., Scarcello E., Caliò F.G. et al., Resection of Carotid Body Tumors reduces arterial blood pressure. An underestimated neuroendocrine syndrome, International Journal of Surgery, 2014, 12, supplement 2, S63-S67 CrossrefGoogle Scholar

  • [53]

    Serra R., Grande R., Buffone G., Scarcello E., Tripodi F., Rende P., et al., Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis, Journal of Pharmacology & Pharmacotherapeutics, 2014, 5, 3, 193-196 PubMedCrossrefGoogle Scholar

  • [54]

    Serra R., Volpentesta G., Gallelli L., Grande R., Buffone G., Lavano A., de Franciscis S., Metalloproteinase-9 and neutrophil gelatinase-associated lipocalin plasma and tissue levels evaluation in middle cerebral artery aneurysms, Br J Neurosurg., 2014, May 5. [Epub ahead of print] PubMedGoogle Scholar

  • [55]

    Di Carlo C., Bonifacio M., Tommaselli G.A., Bifulco G., Guerra G., Nappi C. Metalloproteinases, vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopic endometrium, Fertility and Sterility, 2009, Jun; 91(6), 2315-23,  CrossrefPubMedGoogle Scholar

  • [56]

    L. da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, Mesenchymal stem cells reside in virtually all post-natal organs and tissues, Journal of Cell Science, 2006, 119, 11, 2204-2213 CrossrefPubMedGoogle Scholar

  • [57]

    Hegyi B., Sági B., Kovács J., Kiss J., Urbán V.S., Mészáros G., Monostori E., Uher F., Identical, similar or different? Learning about immunomodulatory function of mesenchymal stem cells isolated from various mouse tissues: bone marrow, spleen, thymus and aorta wall, International Immunology, 2010, 22, 7, 551-559 CrossrefPubMedGoogle Scholar

  • [58]

    D. Tilki, H.-P.Hohn, B. Ergün, S. Rafii, and S. Ergün, Emerging biology of vascular wall progenitor cells in health and disease, Trends in Molecular Medicine, 2009, 15, 11, 501-509 CrossrefPubMedGoogle Scholar

  • [59]

    G. Pasquinelli, A. Pacilli, F.Alviano et al., Multidistrict human mesenchymal vascular cells: pluripotency and stemness characteristics, Cytotherapy, 2010, 12, 3, 275-287 CrossrefPubMedGoogle Scholar

  • [60]

    Ingram D.A., Mead L.E., Moore D.B., Woodard W., Fenoglio A., Yoder M.C., Vesselwall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells, Blood, 2005, 105, 7, 2783-2786 CrossrefPubMedGoogle Scholar

  • [61]

    Campagnolo P., Cesselli D., Al Haj Zen A., Beltrami A.P., Kränkel N., Katare R., et al., Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential, Circulation, 2010, 121, 15, 1735-1745 CrossrefPubMedGoogle Scholar

  • [62]

    Klein D., Benchellal M., Kleff V., Jakob H.G., Ergün S., Hox genes are involved in vascular wall-resident multipotent stem cell differentiation into smooth muscle cells, Scientific Reports, 2013, 3, article 2178 Google Scholar

  • [63]

    Cook D. and Genever P., Regulation of mesenchymal stem cell differentiation, Advances in Experimental Medicine and Biology, 2013, 786, 213-229 CrossrefPubMedGoogle Scholar

  • [64]

    Passman J.N., Dong X.R., Wu S.P., Maguire C.T., Hogan K.A., Bautch V.L., Majesky M.W., A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells, Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 27, 9349-9354 CrossrefPubMedGoogle Scholar

  • [65]

    Zengin E., Chalajour F., Gehling U.M., Ito W.D., Treede H., Lauke H., et al., Vascular wall resident progenitor cells: a source for postnatal vasculogenesis, Development, 2006, 133, 8, 1543-1551 PubMedCrossrefGoogle Scholar

  • [66]

    Risau W., Differentiation of endothelium, The FASEB Journal, 1995, 9, 10, 926-933, 1995 CrossrefGoogle Scholar

  • [67]

    Jain R. K., Molecular regulation of vessel maturation, Nature Medicine, 2003, 9, 6, 685-693 CrossrefPubMedGoogle Scholar

  • [68]

    Carmeliet P., Manipulating angiogenesis in medicine, Journal of Internal Medicine, 2004, 255, 5, 538-561 CrossrefPubMedGoogle Scholar

  • [69]

    Fischer C., Schneider M., and Carmeliet P., Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis, in The Vascular Endothelium II, 2006, 176 of Handbook of Experimental Pharmacology, part 2, 157-212, Springer, Berlin, Germany Google Scholar

  • [70]

    Moore K. A. and Lemischka I. R., Stem cells and their niches, Science, 2006, 311, 5769, 1880-1885 PubMedCrossrefGoogle Scholar

  • [71]

    Ribatti D., Nico B., and Crivellato E., The role of pericytes in angiogenesis, International Journal of Developmental Biology, 2011, 55, 3, 261-268 CrossrefGoogle Scholar

  • [72]

    Khmelewski E., Becker A., Meinertz T., and Ito W. D., Tissue resident cells play a dominant role in arteriogenesis and concomitant macrophage accumulation, Circulation Research, 2004, 95, 6, E56-E64 Google Scholar

  • [73]

    Heil M., Ziegelhoeffer T., Wagner S., Fernández B., Helisch A., Martin S., et al., Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2, Circulation Research, 2004, 94, 5, 671-677 PubMedCrossrefGoogle Scholar

  • [74]

    Invernici G., Madeddu P., Emanueli C., Parati E. A., and Alessandri G., Human fetal aorta-derived vascular progenitor cells: identification and potential application in ischemic diseases, Cytotechnology, 2008, 58, 1, 43-47 CrossrefPubMedGoogle Scholar

  • [75]

    Fang B., Li Y., Song Y., and Li N., Isolation and characterization of multipotent progenitor cells from the human fetal aorta wall, Experimental Biology and Medicine, 2010, 235, 1, 130-138 CrossrefGoogle Scholar

  • [76]

    Yoshimura K., Aoki H., Ikeda Y., Furutani A., Hamano K., Matsuzaki M., Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase, Nature Medicine, 2005, 11, 12, 1330-1338 PubMedCrossrefGoogle Scholar

  • [77]

    Jones G. T., Matrix metalloproteinases in biologic samples, Advances in Clinical Chemistry, 2014, 65, 199-219 PubMedCrossrefGoogle Scholar

  • [78]

    Serra R., Grande R., Montemurro R., Butrico L., Caliò F.G., Mastrangelo D. et al., The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms, Surgery, 2015, 157, 1, 155-162 CrossrefPubMedGoogle Scholar

  • [79]

    Serra R., Buffone G., Falcone D., Molinari V., Scaramuzzino M., Gallelli L., de Franciscis S.., Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin, Wound Repair and Regeneration, 2013, 21, 3, 395-401 CrossrefGoogle Scholar

  • [80]

    R. Serra, R. Grande, G. Buffone et al., Effects of glucocorticoids and TNF-alfa inhibitors on both clinical and molecular parameters in patients with Takayasu Arteritis, Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 3, 193-196 CrossrefGoogle Scholar

  • [81]

    Di Nezza F., Zuccolo E., Poletto V., Rosti V., De Luca A., Moccia F., et al., Liposomes as a Putative Tool to Investigate NAADP Signaling in Vasculogenesis. J Cell Biochem. 2017 Apr 4. . [Epub ahead of print] CrossrefGoogle Scholar

  • [82]

    Bellon G., Martiny L., and Robinet A., Matrix metalloproteinases and matrikines in angiogenesis, Critical Reviews in Oncology/Hematology, 2004, 49, 3, 203-220 CrossrefPubMedGoogle Scholar

  • [83]

    Rundhaug J. E., Matrix metalloproteinases and angiogenesis, Journal of Cellular and Molecular Medicine, 2005, 9, 2, 267-285 PubMedCrossrefGoogle Scholar

  • [84]

    Heissig B., Hattori K., Friedrich M., Rafii S., and Werb Z., Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases, Current Opinion in Hematology, 2003, 10, 2, 136-141 PubMedCrossrefGoogle Scholar

  • [85]

    Risau W., Mechanisms of angiogenesis, Nature, 1997, 386, 6626, 671-674 PubMedCrossrefGoogle Scholar

  • [86]

    Betsholtz C., Lindblom P., and Gerhardt H., Role of pericytes in vascular morphogenesis, EXS, 2005, 94, 115-125 Google Scholar

  • [87]

    Armulik A., Genove G., and Betsholtz C., Pericytes: developmental, physiological, and pathological perspectives, problems, and promises, Developmental Cell, 2011, 21, 2, 193-215 PubMedCrossrefGoogle Scholar

  • [88]

    Liu Y. and Senger D. R., Matrix-specific activation of Src amid Rho initiates capillary morphogenesis of endothelial cells, The FASEB Journal, 2004, 18, 3, 457-468 CrossrefGoogle Scholar

  • [89]

    Stratman A. N. and Davis G. E., Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization, Microscopy andMicroanalysis, 2012, 18, 1, 68-80 CrossrefGoogle Scholar

  • [90]

    Stratman A. N., K. Malotte M., Mahan R. D., Davis M. J., and Davis G. E., Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation, Blood, 2009, 114, 24, 5091-5101 PubMedCrossrefGoogle Scholar

  • [91]

    Perlmutter L. S. and Chui H. C., Microangiopathy, the vascular basement membrane and Alzheimer’s disease: a review, Brain Research Bulletin, 1990, 24, 5, 677-686 PubMedCrossrefGoogle Scholar

  • [92]

    Reisig K. and Clyne A. M., Fibroblast growth factor-2 binding to the endothelial basement membrane peaks at a physiologically relevant shear stress, Matrix Biology, 2010 29, 7, 586-593 CrossrefGoogle Scholar

  • [93]

    Nikolova G., Jabs N., Konstantinova I., Domogatskaya A., Tryggvason K. et al., The vascular basement membrane: a niche for insulin gene expression and β cell proliferation, Developmental Cell, 2006, 10, 3, 397-405 CrossrefPubMedGoogle Scholar

  • [94]

    Soltani A., Reid D.W., Sohal S.S., Wood-Baker R., Weston S., Muller H.K., Walters E.H., Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study, Respiratory Research, 11, article 105 Google Scholar

  • [95]

    R. Wiggins, M. Goyal, S. Merritt, and P. D. Killen, Vascular adventitial cell expression of collagen I messenger ribonucleic acid in anti-glomerular basement membrane antibody-induced crescentic nephritis in the rabbit: a cellular source for interstitial collagen synthesis in inflammatory renal disease, Laboratory Investigation, 2010, 68, 5, 557-565, 1993 Google Scholar

  • [96]

    Geevarghese A. and Herman I. M., Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies, Translational Research, 2014, 163, 4, 296-306 CrossrefGoogle Scholar

  • [97]

    Orlova V.V., Drabsch Y., Freund C., Petrus-Reurer S., van den Hil F.E., Muenthaisong S., et al., Functionality of endothelial cells and pericytes from human pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish xenografts, Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1, 177-186 CrossrefGoogle Scholar

  • [98]

    Carmeliet P. and Jain R. K., Molecular mechanisms and clinical applications of angiogenesis, Nature, 2011, 473, 7347, 298-307 PubMedCrossrefGoogle Scholar

  • [99]

    Chen X. and Li Y., Role ofmatrixmetalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis, Cell Adhesion and Migration, 2009, 3, 4, 337-341 CrossrefGoogle Scholar

  • [100]

    Page-McCaw A., Ewald A. J., and Werb Z., Matrix metalloproteinases and the regulation of tissue remodelling, Nature Reviews Molecular Cell Biology, 2007, 8, 3, 221-233 CrossrefPubMedGoogle Scholar

  • [101]

    Johnson J. L., Dwivedi A., Somerville M., George S. J., and Newby A. C., Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smoothmuscle cell migration and neointima formation in mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 9, e35-e44 Google Scholar

  • [102]

    E. R. Isenović, M. H. Kedees, S. Tepavćević et al., Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation, Cardiovascular and Hematological Disorders.Drug Targets, 2009, 9, 3, 172-180 Google Scholar

  • [103]

    Isenović E.R., Soskić S., Trpković A., Dobutović B., Popović M., Gluvić Z., Putniković B., Marche P.., Insulin, thrombin, ERK1/2 kinase and vascular smooth muscle cells proliferation, Current Pharmaceutical Design, 2010, 16, 35, 3895-3902 PubMedCrossrefGoogle Scholar

  • [104]

    Smiljanic K., Obradovic B., Obradovic M., Nikolic D., Marche P., and Isenovic E. R., Involvement of the ADAM 12 in thrombin-induced rat’s VSMCs proliferation, Current Medicinal Chemistry, 2011, 18, 22, 3382-3386 PubMedCrossrefGoogle Scholar

  • [105]

    M.Matrisian L. and Hogan B. L., Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development, Current topics in developmental biology, 1990, 24, 219-259 CrossrefPubMedGoogle Scholar

  • [106]

    Yang K., Palm J., König J., Seeland U., Rosenkranz S., Feiden W. et al., Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury, International Journal of Radiation Biology, 2007, 83, 10, 665-676 PubMedCrossrefGoogle Scholar

  • [107]

    Pruett N. D., Hajdu Z., Zhang J., Visconti R.P., Kern M.J., Wellik D.M. et al., Changing topographic Hox expression in blood vessels results in regionally distinct vessel wall remodeling, Biology Open, 2012, 1, 5, 430-435 CrossrefPubMedGoogle Scholar

  • [108]

    Hungerford J. E., Owens G. K., Argraves W. S., and Little C. D., Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers, Developmental Biology, 1996, 178, 2, 375-392 CrossrefPubMedGoogle Scholar

  • [109]

    Carion A., Benboubker L., Herault O., Roingeard F., Degenne M., Senecal D., et al., Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells, British Journal of Haematology, 2003 122, 6, 918-926 Google Scholar

  • [110]

    Steinl C., Essl M., Schreiber T.D., Geiger K., Prokop L., Stevanović S. et al., Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells, Stem Cells and Development, 2013, 22, 9, 1307-1318 PubMedCrossrefGoogle Scholar

  • [111]

    Berger M., Bergers G., Arnold B., Hämmerling G.J., and Ganss R., Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization, Blood, 2005, 105, 3, 1094-1101 PubMedGoogle Scholar

  • [112]

    Lo R. C., Lu B., M. Fokkema T.M., Conrad M., Patel VI., Fillinger M. et al., Relative importance of aneurysm diameter and body size for predicting abdominal aortic aneurysm rupture in men and women, Journal of Vascular Surgery, 2014, 59, 5, 1209-1216 PubMedCrossrefGoogle Scholar

  • [113]

    Farnoush A., Avolio A., and Qian Y., A growth model of saccular aneurysms based on hemodynamic and morphologic discriminant parameters for risk of rupture, Journal of Clinical Neuroscience, 2014, 21, 9, 1514-1519 CrossrefGoogle Scholar

  • [114]

    Sainz J., Zen A. A. H., Caligiuri G., Demerens C., Urbain D., Lemitre M., et al., Isolation of ‘side population’ progenitor cells from healthy arteries of adult mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2, 281-286 Google Scholar

  • [115]

    Liu Z. J., T. Shirakawa T., Li Y., Soma A., Oka M., Dotto GP., et al., Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis, Molecular and Cellular Biology, 2003, 23, 1, 14-25 PubMedCrossrefGoogle Scholar

  • [116]

    Gridley T., Notch signaling in the vasculature, Current Topics in Developmental Biology, 2010, 92, 277-309 CrossrefPubMedGoogle Scholar

  • [117]

    Morrow D., Guha S., Sweeney C., Birney Y., Walshe T., O’Brien C., et al., Notch and vascular smooth muscle cell phenotype, Circulation Research, 2008, 103, 12, 1370-1382 CrossrefPubMedGoogle Scholar

  • [118]

    Schrimpf C., Teebken O.E., Wilhelmi M., and Duffield J.S., The role of pericyte detachment in vascular rarefaction, Journal of Vascular Research, 2014, 51, 4, 247-258 CrossrefPubMedGoogle Scholar

  • [119]

    Schrimpf C., and Duffield J.S., Mechanisms of fibrosis: the role of the pericyte, Current Opinion in Nephrology and Hypertension, 2011, 20, 3, 297-305 PubMedCrossrefGoogle Scholar

  • [120]

    Uzui H., Lee J.D., Shimizu H., Tsutani H., and Ueda T., The role of protein-tyrosine phosphorylation and gelatinase production in themigration and proliferation of smooth muscle cells, Atherosclerosis, 2000, 149, 1, 51-59 PubMedCrossrefGoogle Scholar

  • [121]

    Sternlicht M.D., and Werb Z., How matrix metalloproteinases regulate cell behavior, Annual Review of Cell and Developmental Biology, 2001, 17, 463-516 PubMedCrossrefGoogle Scholar

  • [122]

    Raffetto J. D., and Khalil R. A., Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease, Biochemical Pharmacology, 2008, 75, 2, 346-359 PubMedCrossrefGoogle Scholar

  • [123]

    Park H.S., Choi G.H., Hahn S., Yoo Y.S., Lee J.Y., and Lee T., Potential role of vascular smooth muscle cell-like progenitor cell therapy in the suppression of experimental abdominal aortic aneurysms, Biochemical and Biophysical Research Communications, 2013, 431, 2, 326-331 CrossrefPubMedGoogle Scholar

  • [124]

    Galis Z. S. and Khatri J. J., Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly, Circulation Research, 2002, 90, 3, 251-262 PubMedGoogle Scholar

  • [125]

    Tamarina N.A., D.McMillan W., Shively V. P., and Pearce W.H., Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta, Surgery, 1997, 122, 2, 264-272 PubMedCrossrefGoogle Scholar

  • [126]

    Ryer E.J., Garvin R. P., Schworer C. M. Bernard-Eckroth K.R., Tromp G., Franklin D.P., et al., Proinflammatory role of stem cells in abdominal aortic aneurysms, Journal of Vascular Surgery, 2015, 62, (5), 1303-11.e4.  CrossrefPubMedGoogle Scholar

  • [127]

    Pasquinelli G., Tazzari P.L., Vaselli C., Foroni L., Buzzi M., Storci G., et al., Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic mesenchymal stromal cells, Stem Cells, 2007, 25, 7, 1627-1634 CrossrefPubMedGoogle Scholar

  • [128]

    Invernici G., Emanueli C., Madeddu P., Cristini S., Gadau S., Benetti A., et al., Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia, The American Journal of Pathology, 2007, 170, 6, 1879-1892 CrossrefGoogle Scholar

  • [129]

    Zhang C., Zeng L., Emanueli C., and Xu Q., Blood flow and stem cells in vascular disease, Cardiovascular Research, 2013, 99, 2, 251-259 CrossrefPubMedGoogle Scholar

  • [130]

    Kawabe J.I., and Hasebe N., Role of the vasa vasorum and vascular resident stem cells in atherosclerosis, BioMed Research International, 2014, Article ID 701571 PubMedGoogle Scholar

  • [131]

    Hu Y., and Xu Q., Adventitial biology, differentiation and function, Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1523-1529 CrossrefPubMedGoogle Scholar

  • [132]

    Gutterman D.D., Adventitia-dependent influences on vascular function, American Journal of Physiology—Heart and Circulatory Physiology, 1999, 277, 4, H1265-H1272 Google Scholar

  • [133]

    Michel J.B., Thaunat O., Houard X., Meilhac O., Caligiuri G,, and Nicoletti A., Topological determinants and consequences of adventitial responses to arterial wall injury, Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 6, 1259-1268 CrossrefPubMedGoogle Scholar

  • [134]

    Wilcox J.N., Okamoto E.I., Nakahara K.I., and Vinten-Johansen J., Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblast precursors? Annals of the New York Academy of Sciences, 2001, 947, 68-92 PubMedGoogle Scholar

  • [135]

    Fukuda D., Enomoto S., Nagai R., and Sata M., Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation, Biomedicine and Pharmacotherapy, 2009, 63, 10, 754-761 CrossrefGoogle Scholar

  • [136]

    Mitchell R.N., and Libby P., Vascular remodeling in transplant vasculopathy, Circulation Research, 2007, 100, 7, 967-978 PubMedCrossrefGoogle Scholar

  • [137]

    Shi G.P. and. Lindholt J.S, Mast cells in abdominal aortic aneurysms, Current Vascular Pharmacology, 2013, 11, 3, 314-326 CrossrefPubMedGoogle Scholar

  • [138]

    Witte J.T., Hasson J.E.,. Harms B.A, Corrigan T.E., and Love R.B., Fatal gastric artery dissection and rupture occurring as a paraesophageal mass: a case report and literature review, Surgery, 1990, 107, 5, 590-594 Google Scholar

  • [139]

    Shen Y.H., Hu X., Zou S., Wu D., Coselli J.S., and Lemaire S.A., Stem cells in thoracic aortic aneurysms and dissections: potential contributors to aortic repair, Annals of Thoracic Surgery, 2012, 93, 5, 1524-1533 CrossrefGoogle Scholar

  • [140]

    Curci J.A., and Thompson R.W., Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context? The Journal of Clinical Investigation, 2004, 114, 2, 168-171 CrossrefPubMedGoogle Scholar

  • [141]

    Xiong W., Zhao Y., Prall A., Greiner T.C., and Baxter B.T., Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model, Journal of Immunology, 2004, 172, 4, 2607-2612 CrossrefGoogle Scholar

  • [142]

    Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T., Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms, The Journal of Clinical Investigation, 2002, 110, 5, 625-632 PubMedCrossrefGoogle Scholar

  • [143]

    Ikonomidis J.S., Barbour J.R., Amani Z., Stroud R.E., Herron A.R., McClister D.M. Jr., et al., Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms, Circulation, 2005, 112, 9, supplement, I242-I248 Google Scholar

  • [144]

    Klein D., Weißhardt P., Kleff V., Jastrow H., Jakob H.G., and Ergün S., Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation, PLoS ONE, 2011, 6, 5, Article ID e20540 Google Scholar

  • [145]

    Chan-Ling T., Koina M.E., McColm J.R., Dahlstrom J.E., Bean E., Adamson S., et al., Role of CD44+ stem cells in mural cell formation in the human choroid: evidence of vascular instability due to limited pericyte ensheathment, Investigative Ophthalmology and Visual Science, 2011, 52, 1, 399-410 CrossrefGoogle Scholar

  • [146]

    Vasuri F., Fittipaldi S., and Pasquinelli G., Arterial calcification: finger-pointing at resident and circulating stem cells, World Journal of Stem Cells, 2014, 6, 5, 540-551 PubMedCrossrefGoogle Scholar

  • [147]

    Hu Y., Zhang Z., Torsney E., Afzal AR., Davison F., Metzler B., et al., Abundant progenitor cells in the adventitia contribute to atheroscleroses of vein grafts in ApoE-deficient mice, The Journal of Clinical Investigation, 2004, 113, 9, 1258-1265 PubMedCrossrefGoogle Scholar

  • [148]

    Torsney E., Hu Y., and Xu Q., Adventitial progenitor cells contribute to arteriosclerosis, Trends in Cardiovascular Medicine, 2005, 15, 2, 64-68 PubMedCrossrefGoogle Scholar

  • [149]

    Margariti A., Zeng L., and Xu Q., Stem cells, vascular smooth muscle cells and atherosclerosis, Histology and Histopathology, 2006, 21, 7-9, 979-985 PubMedGoogle Scholar

  • [150]

    Torsney E., Mandal K., Halliday A., Jahangiri M., and Xu Q., Characterisation of progenitor cells in human atherosclerotic vessels, Atherosclerosis, 2007, 191, 2, 259-264 PubMedCrossrefGoogle Scholar

  • [151]

    Tigges U., M. Komatsu M., and Stallcup W.B., Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury, Journal of Vascular Research, 2013, 50, 2, 134-144 PubMedCrossrefGoogle Scholar

  • [152]

    Grudzinska M.K., Kurzejamska E., Bojakowski K., Soin J., Lehmann MH., Reinecke H., et al., Monocyte chemoattractant protein 1-mediated migration of mesenchymal stem cells is a source of intimal hyperplasia, Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 6, 1271-1279 CrossrefPubMedGoogle Scholar

  • [153]

    Si Y., Ren J., Wang P., Rateri D.L., Daugherty A., Shi X.D., et al., Protein kinase C-delta mediates adventitial cell migration through regulation of monocyte chemoattractant protein-1 expression in a rat angioplasty model, Arteriosclerosis, Thrombosis, and Vascular Biology, 2012 32, 4, 943-954 CrossrefGoogle Scholar

  • [154]

    Ma X.L., Liu K.D., Li F.C., Jiang X.M., Jiang L., and Li H.L., Human mesenchymal stem cells increases expression of -tubulin and angiopoietin 1 and 2 in focal cerebral ischemia and reperfusion, Current Neurovascular Research, 2013, 10, 2, 103-111 PubMedCrossrefGoogle Scholar

  • [155]

    Onda T., Honmou O., Harada K., Houkin K., Hamada H., and Kocsis J.D., Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia, Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 2, 329-340 CrossrefGoogle Scholar

  • [156]

    Tellides G., and Pober J.S., Inflammatory and immune responses in the arterial media, Circulation Research, 2015, 116, 2, 312-322 PubMedCrossrefGoogle Scholar

  • [157]

    Lacolley P., Regnault V., Nicoletti A., Li Z., and Michel J.B., The vascular smoothmuscle cell in arterial pathology: a cell that can take on multiple roles, Cardiovascular Research, 2012, 95, 2, 194-204 CrossrefGoogle Scholar

  • [158]

    Luster A.D., Alon R., and von Andrian U.H., Immune cell migration in inflammation: present and future therapeutic targets, Nature Immunology, 2005, 6, 12, 1182-1190 PubMedCrossrefGoogle Scholar

  • [159]

    Ma S., Xie N., Li W., Yuan B., Shi Y., and Wang Y., Immunobiology of mesenchymal stem cells, Cell Death and Differentiation, 2014, 21, 2, 216-225 PubMedCrossrefGoogle Scholar

  • [160]

    Shi Y., Su J., Roberts A.I., Shou P., Rabson A.B., and Ren G., How mesenchymal stem cells interact with tissue immune responses, Trends in Immunology, 2012, 33, 3, 136-143 PubMedCrossrefGoogle Scholar

  • [161]

    Kassem M., Abdallah B.M., and Saeed H., Osteoblastic cells: differentiation and trans-differentiation, Archives of Biochemistry and Biophysics, 2008, 473, 2, 183-187 CrossrefPubMedGoogle Scholar

  • [162]

    Sata M., Tanaka K., and Nagai R., Circulating osteoblastlineage cells, The New England Journal of Medicine, 2005, 353, 7, 737-738 CrossrefPubMedGoogle Scholar

  • [163]

    Pignolo R.J., and Shore E.M., Circulating osteogenic precursor cells, Critical Reviews in Eukaryotic Gene Expression, 2010, 20, 2, 171-180 CrossrefPubMedGoogle Scholar

  • [164]

    Rennert R.C., Sorkin M., Garg R.K., and Gurtner G.C., Stem cell recruitment after injury: lessons for regenerative medicine, Regenerative Medicine, 2012, 7, 6, 833-850 PubMedCrossrefGoogle Scholar

  • [165]

    Bertoncello I. and Mcqualter J.L., Endogenous lung stem cells: what is their potential for use in regenerative medicine? Expert Review of Respiratory Medicine, 2010, 4, 3, 349-362 CrossrefPubMedGoogle Scholar

  • [166]

    Guan S., Wang Z., Xin F., and Xin H., Wnt5a is associated with the differentiation of bone marrow mesenchymal stem cells in vascular calcification by connecting with different receptors, Molecular Medicine Reports, 2014, 10, 4, 1985-1991 PubMedCrossrefGoogle Scholar

  • [167]

    Endo I. and Mastumoto T., Bone and stem cells. Regulatory mechanism of mesenchymal stem cell differentiation to osteoblasts, Clinical Calcium, 2014, 24, 4, 555-564 PubMedGoogle Scholar

  • [168]

    Callegari A., Coons M.L., Ricks J.L., Yang H.L., Gross T.S., Huber P., et al., Bone marrowor vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification, Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 11, 2491-2500 PubMedCrossrefGoogle Scholar

  • [169]

    Sage A.P., Tintut Y., and Demer L.L., Regulatory mechanisms in vascular calcification, Nature Reviews Cardiology, 2010, 7, 9, 528-536 PubMedCrossrefGoogle Scholar

  • [170]

    Shanahan C.M., Cary N.R.B., Salisbury J.R., Proudfoot D., Weissberg P.L., and Edmonds M.E., Medial localization of mineralization-regulating proteins in association with Mönckeberg’s sclerosis: evidence for smooth muscle cell mediated vascular calcification, Circulation, 1999, 100, 21, 2168-2176 PubMedCrossrefGoogle Scholar

  • [171]

    Tyson K.L., Reynolds J.L., McNair R., Zhang Q., Weissberg P.L., and Shanahan C.M., Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification, Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 3, 489-494 PubMedCrossrefGoogle Scholar

  • [172]

    Brighton C.T., Lorich D.G., Kupcha R., Reilly T.M., Jones A.R., and Woodbury II R.A., The pericyte as a possible osteoblast progenitor cell, Clinical Orthopaedics and Related Research, 1992, 275, 287-299 Google Scholar

  • [173]

    Diaz-Flores L., Gutierrez R., Lopez-Alonso A., Gonzalez R., and Varela H., Pericytes as a supplementary source of osteoblasts in periosteal osteogenesis, Clinical Orthopaedics and Related Research, 1992, 275, 280-286 Google Scholar

  • [174]

    Díaz-Flores L., Gutiérrez R., Madrid J.F., Varela H., Valladares F., Acosta E., et al., Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche, Histology and Histopathology, 2009, 24, 7, 909-969 Google Scholar

  • [175]

    Liu J., Xiong W., Baca-Regen L., Nagase H., and Baxter B.T., Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells, Journal of Vascular Surgery, 2003, 38, 6, 1376-1383 PubMedCrossrefGoogle Scholar

  • [176]

    Muller P., Beltrami A.P., Cesselli D., Pfeiffer P., Kazakov A., and Böhm M., Myocardial regeneration by endogenous adult progenitor cells, Journal of Molecular and Cellular Cardiology, 2005, 39, 2, 377-387 CrossrefPubMedGoogle Scholar

  • [177]

    Xie X., Sun A., Huang Z., Zhu W., Wang S., Zou Y., et al., Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells, Medical Hypotheses, 2011, 76, 3, 365-367 CrossrefPubMedGoogle Scholar

  • [178]

    Friedrich E.B., K. Walenta K., J. Scharlau J., G. Nickenig G., and N. Werner N., CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities, Circulation Research, 2006, 98, 3, e20-e25 Google Scholar

  • [179]

    Zuccolo E., Bottino C., Diofano F., Poletto V., Codazzi AC., Mannarino S., et al., Constitutive store-operated Ca2+ entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma-derived endothelial colony forming cells, Stem Cells Dev, 2016 Feb 15, 25, (4), 301-19,  CrossrefGoogle Scholar

  • [180]

    Poletto V., Dragoni S., Lim D., Biggiogera M., Aronica A., Cinelli M., et al., Endoplasmic Reticulum Ca2+ Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells, J Cell Biochem, 2016, 117, (10), 2260-71,  CrossrefGoogle Scholar

  • [181]

    Berra-Romani R., Avelino-Cruz J.E., Raqeeb A., Della Corte A., Cinelli M., Montagnani S., et al., Ca2+-dependent nitric oxide release in the injured endothelium of excised rat aorta: a promising mechanism applying in vascular prosthetic devices in aging patients, BMC Surg, 2013, 13, (Suppl 2), S40,  CrossrefGoogle Scholar

  • [182]

    Berra-Romani R., Raqeeb A., Torres-Jácome J., Guzman-Silva A., Guerra G., Tanzi F., et al., The mechanism of injuryinduced intracellular calcium concentration oscillations in the endothelium of excised rat aorta, J Vasc Res, 2012, 49, (1), 65-76,  CrossrefGoogle Scholar

  • [183]

    Dragoni S., Turin I., Laforenza U., Potenza D.M., Bottino C., Glasnov T.N., et al., Store-operated ca(2+) entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma, Biomed Res Int, 2014,739494,  CrossrefPubMedGoogle Scholar

  • [184]

    Lodola F., Laforenza U., Bonetti E., Lim D., Dragoni S., Bottino C., et al., Store operated Ca2+ entry is remodelled and controls in vivo angiogenesis in endothelial progenitor cells isolated from tumoral patients, PLoS One, 2012, 7, (9), e42541 CrossrefGoogle Scholar

  • [185]

    Dragoni S., Laforenza U., Bonetti E., Reforgiato M., Poletto V., Lodola F., Bottino C., et al., Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis, PLoS One 2014, 9, (3), e91099,  CrossrefPubMedGoogle Scholar

  • [186]

    Moccia F., Dragoni S., Lodola F., Bonetti E., Bottino C., Guerra G., et al., Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell based therapy and adverse tumour vascularization, Curr Med Chem, 2012, 19, 5802-5818,  CrossrefGoogle Scholar

  • [187]

    Moccia F., Lodola F., Dragoni S., Bonetti E., Bottino C., Guerra G., et al., Signalling in endothelial pro genitor cells: a novel means to improve cell-based therapy and impair tumour vascularization, Curr Vasc Pharmacol, 2014, 12, 87-105,  CrossrefGoogle Scholar

  • [188]

    Dragoni S., Reforgiato M., Zuccolo E., Poletto V., Lodola F., Ruffinatti FA., et al., Dysregulation of VEGF-induced pro-angiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony forming cells, Exp Hematol, 2015, 43, (12), 1019-1030 e3,  CrossrefGoogle Scholar

  • [189]

    Moccia F., Zuccolo E., Poletto V., Cinelli M., Bonetti E., Guerra G., et al., Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy, Tumour Biol, 2015, 36, (9), 6603-14,  CrossrefPubMedGoogle Scholar

  • [190]

    Poletto V., Galimberti V., Guerra G., Rosti V., Moccia F., Biggiogera M., Fine structural detection of calcium ions by photoconversion, European Journal of Histochemistry, 2016, 60, (3), 2695,  CrossrefGoogle Scholar

  • [191]

    Zuccolo E., Dragoni S., Poletto V., Catarsi P., Guido D., Rappa A., et al., Arachidonic acid-evoked Ca2+ signals promote nitric oxide release and proliferation in human endothelial colony forming cells, Vascul Pharmacol, 2016, 87, 159-171,  CrossrefPubMedGoogle Scholar

  • [192]

    Rippa E., Altieri F., Di Stadio C.S., Miselli G., Lamberti A., Federico A., et al., Ectopic expression of gastrokine 1 in gastric cancer cells up-regulates tight and adherens junction proteins network, Pathol Res Pract, 2015, 211, (8), 577-83,  CrossrefPubMedGoogle Scholar

  • [193]

    Trollope A., Moxon J.V., Moran C.S., and Golledge J., Animal models of abdominal aortic aneurysm and their role in furthering management of human disease, Cardiovascular Pathology, 2011, 20, 2, 114-123 CrossrefGoogle Scholar

  • [194]

    Uccelli A., Moretta L., and PistoiaV., Immunoregulatory function of mesenchymal stem cells, European Journal of Immunology, 2006, 36, 10, 2566-2573 PubMedCrossrefGoogle Scholar

  • [195]

    Kiss J., Urbán V.S., Dudics V., Vas V., and Uher F., Mesenchymal stem cells and the immune system—immunosuppression without drugs? Orvosi Hetilap, 2008, 149, 8, 339-346 PubMedCrossrefGoogle Scholar

  • [196]

    Planat-Benard V., Silvestre J.S., Cousin B., André M., Nibbelink M., Tamarat R., et al., Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives, Circulation, 2004, 109, 5, 656-663 PubMedCrossrefGoogle Scholar

  • [197]

    Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., et al., Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells, Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 12, 2542-2547 CrossrefPubMedGoogle Scholar

  • [198]

    Miranville A., Heeschen C., Sengenès C., Curat C.A., Busse R., and Bouloumiè A., Improvement of postnatal neovascularization by human adipose tissue-derived stem cells, Circulation, 2004, 110, 3, 349-355 PubMedCrossrefGoogle Scholar

  • [199]

    Grøgaard H.K., Sigurjonsson O.E., Brekke M., Kløw N.E., Landsverk K.S., Lyberg T., et al., Cardiac accumulation of bone marrow mononuclear progenitor cells after intracoronary or intravenous injection in pigs subjected to acute myocardial infarction with subsequent reperfusion, Cardiovascular Revascularization Medicine, 2007, 8, 1, 21-27 CrossrefGoogle Scholar

  • [200]

    Henning R.J., Stem cells in cardiac repair, Future Cardiology, 2011, 7, 1, 99-117 PubMedCrossrefGoogle Scholar

  • [201]

    Yang Z., Zhang F., Ma W., Chen B., Zhou F., Xu Z., et al., A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarctrelative artery, Cardiovascular Therapeutics, 2010, 28, 6, 380-385 CrossrefGoogle Scholar

  • [202]

    Lalu M.M., McIntyre L., Pugliese C., Fergusson D., Winston B.W., Marshall J.C., et al., Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials, PLoS ONE, 2012, 7, 10, Article ID e47559 Google Scholar

  • [203]

    Williams A.R., Hatzistergos K.E., Addicott B., McCall F., Carvalho D., Suncion V., et al., Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction, Circulation, 2013, 127, 2, 213-223 PubMedCrossrefGoogle Scholar

  • [204]

    Moccia F., Zuccolo E., Poletto V., Turin I., Guerra G., Pedrazzoli P., et al., Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. Curr Med Chem. 2016, 23, (30), 3450-3480,  CrossrefPubMedGoogle Scholar

  • [205]

    Oskouei B.N., Lamirault G., Joseph C., Treuer A.V., Landa S., Da Silva J., .et al., Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair, Stem Cells Translational Medicine, 2012, 1, 2, 116-124 PubMedCrossrefGoogle Scholar

  • [206]

    Tang X.L., Rokosh D.G., Guo Y., and Bolli R., Cardiac progenitor cells and bone marrow-derived very small embryonic like stem cells for cardiac repair after myocardial infarction, Circulation Journal, 2010, 74, 3, 390-404 CrossrefGoogle Scholar

  • [207]

    Péault B., Rudnicki M., Torrente Y., Cossu G., Tremblay J.P., Partridge T., et al., Stem and progenitor cells in skeletal muscle development, maintenance, and therapy, Molecular Therapy, 2007, 15, 5, 867-877 CrossrefGoogle Scholar

  • [208]

    Mitchell K.J., Pannérec A., Cadot B., Parlakian A., Besson V., Gomes E.R., et al., Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development, Nature Cell Biology, 2010, 12, 3, 257-266 PubMedGoogle Scholar

  • [209]

    Wallace G.Q., and McNally E.M., Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies, Annual Review of Physiology, 2009, 71, 37-57 PubMedCrossrefGoogle Scholar

  • [210]

    Rahimov F., and Kunkel L.M., Cellular and molecular mechanisms underlying muscular dystrophy, Journal of Cell Biology, 2013, 201, 4, 499-510 CrossrefGoogle Scholar

  • [211]

    Corselli M., Chen C.W., Crisan M., Lazzari L., and PéaultB., Perivascular ancestors of adult multipotent stem cells, Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 6, 1104-1109 CrossrefGoogle Scholar

  • [212]

    Dellavalle A., Sampaolesi M., Tonlorenzi R., Tagliafico E., Sacchetti B., Perani L., et al., Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells, Nature Cell Biology, 2007, 9, 3, 255-267 PubMedCrossrefGoogle Scholar

  • [213]

    Farini A., Razini P., Erratico S., Torrente Y., and Meregalli M., Cell based therapy for duchenne muscular dystrophy, Journal of Cellular Physiology, 221, 3, 526-534, 2009 Google Scholar

  • [214]

    Huang G.T., Yamaza T., Shea L.D., Djouad F., Kuhn N.Z., Tuan R.S., et al., Stem/progenitor cell-mediated de novo regeneration of dental pulp with newly deposited continuous layer of dentin in an in vivo model, Tissue Engineering Part A, 2010, 16, 2, 605-615 CrossrefGoogle Scholar

  • [215]

    Bianco P., Sacchetti B., and Riminucci M., Osteoprogenitors and the hematopoietic microenvironment, Best Practice and Research: Clinical Haematology, 2011, 24, 1, 37-47 Google Scholar

  • [216]

    Shi S., and Gronthos S., Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp, Journal of Bone and Mineral Research, 2003, 18, 4, 696-704 CrossrefGoogle Scholar

  • [217]

    Morigi M., Rota C., Montemurro T., Montelatici E., Lo Cicero V., Imberti B., et al., Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury, Stem Cells, 2010, 28, 3, 513-522 PubMedGoogle Scholar

  • [218]

    Asanuma H., Meldrum D.R., and Meldrum K.K., Therapeutic applications of mesenchymal stem cells to repair kidney injury, Journal of Urology, 2010, 184, 1, 26-33 CrossrefGoogle Scholar

  • [219]

    Pochampally R.R., Smith J.R., Ylostalo J., and Prockop D.J., Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes, Blood, 2004, 103, 5, 1647-1652 PubMedCrossrefGoogle Scholar

  • [220]

    Ibberson D., Tremain N., Gray A., and Phinney D.G., What is in a name? Defining the molecular phenotype of marrow stromal cells and their relationship to other stem/progenitor cells, Cytotherapy, 2001, 3, 5, 409-411 CrossrefGoogle Scholar

  • [221]

    laRussa V.F., Schwarzenberger P., Miller A., Agrawal K., Kolls J., and Weiner R., Marrow stem cells, mesenchymal progenitor cells, and stromal progeny, Cancer Investigation, 2002, 20, 1, 110-123 CrossrefPubMedGoogle Scholar

  • [222]

    Montemurro T., Andriolo G., Montelatici E., Weissmann G., Crisan M., Colnaghi M.R., et al., Differentiation and migration properties of human foetal umbilical cord perivascular cells: potential for lung repair, Journal of Cellular and Molecular Medicine, 2011, 15, 4, 796-808 PubMedCrossrefGoogle Scholar

  • [223]

    Covas D.T., Panepucci R.A., Fontes A.M., Silva W.A. Jr, Orellana M.D., Freitas M.C., et al., Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts, Experimental Hematology, 2008, 36, 5, 642-654 CrossrefPubMedGoogle Scholar

  • [224]

    Schweizer R., Kamat P., Schweizer D., Dennler C., Zhang S., Schnider J.T., et al., Bone marrow derived mesenchymal stromal cells improve vascular regeneration and reduce leukocyte-endothelium activation in critical ischemic murine skin in a dose-dependent manner, Cytotherapy, 2014, 16, 10, 1345-1360 CrossrefGoogle Scholar

  • [225]

    Bortolotti F., Ukovich L., Razban V., Martinelli V., Ruozi G., Pelos B., et al., In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure, Stem Cell Reports, 2015, 10, 4, (3), 332-9.  CrossrefGoogle Scholar

  • [226]

    Watt S.M., Gullo F., van der Garde M., Markeson D., Camicia R., Khoo C.P., et al., The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential, British Medical Bulletin, 2013, 108, 1, 25-53 CrossrefPubMedGoogle Scholar

  • [227]

    Cotrufo M., Della Corte A., De Santo L.S., Quarto C., De Feo M., Romano G., et al., Different patterns of extracellular matrix protein expression in the convexity and the concavity of the dilated aorta with bicuspid aortic valve: preliminary results. J Thorac Cadiovasc Surg, 2005, 130, (2), 504-11,  CrossrefGoogle Scholar

  • [228]

    Cotrufo M., De Santo L., Della Corte A., Di Meglio F., Guerra G., Quarto C., et al., Basal lamina structural alterations in human asymmetric aneurismatic aorta. Eur J Histochem, 2005, 49, (4), 363-370 PubMedGoogle Scholar

  • [229]

    Aronow W.S., Peripheral arterial disease and abdominal aortic aneurysm in elderly people, Minerva Medica, 2011, 102, 6, 483-500 PubMedGoogle Scholar

  • [230]

    Kraemer R., Nguyen H., March K.L., and Hempstead B., NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biological responses, Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 4, 1041-1050 CrossrefPubMedGoogle Scholar

  • [231]

    Amato B., Compagna R., Amato M., Grande R., Butrico L., Rossi A., et al., Stem Cells International 2015 Article ID 434962 Google Scholar

  • [232]

    Murray I.R., West C.C., Hardy W.R., James A.W., Park T.S., Nguyen A., et al., Natural history of mesenchymal stem cells, from vessel walls to culture vessels, Cellular and Molecular Life Sciences, 71, 8, 1353-1374, 2014 Google Scholar

  • [233]

    Chaabane C., Otsuka F., Virmani R., and Bochaton-Piallat M.L., Biological responses in stented arteries, Cardiovascular Research, 2013, 99, 2, 353-363 PubMedCrossrefGoogle Scholar

  • [234]

    Zgheib C., Xu J., and Liechty K.W., Targeting inflammatory cytokines and extracellular matrix composition to promote wound regeneration. Advances in Wound Care 2014, 3,(4), 344-355 PubMedCrossrefGoogle Scholar

  • [235]

    Compagna R., Amato B., Massa S., Amato M., Grande R., Butrico L., et al. Cell therapy in patients with critical limb ischemia. Stem Cells International 2015, Article ID 931420.  CrossrefPubMedGoogle Scholar

About the article

*Bruno Amato and Raffaele Serra contributed equally to coordination of this work and share the senior authorship.

Received: 2017-03-19

Accepted: 2017-08-16

Published Online: 2017-10-21

Conflict of interestConflict of interest statement: Authors state no conflict of interest

Citation Information: Open Medicine, Volume 12, Issue 1, Pages 308–322, ISSN (Online) 2391-5463, DOI: https://doi.org/10.1515/med-2017-0045.

Export Citation

© 2017 Aldo Rocca et al.. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. BY-NC-ND 4.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Comments (0)

Please log in or register to comment.
Log in